mmg71 Posted - 58 minutes from now

$BCTX brain cancer market size $2 bb, breast cancer market size $30 bb… and we have an effective product and MC $22 mm with $14 mm cash… $DRUG $PFE $MRK

pnvoss Posted - 7 hours ago

$SPY $MRK and $PFE are the setups I like

pnvoss Posted - 7 hours ago

$SPY pounding the table on $PFE and $MRK . 6 month swing. Very low rsi and mfi readings. Curling up from lows. $MRK just above 5 yr support . $PFE very oversold and low mfi readings. Both 65% undervalued to future cash flow

pnvoss Posted - 11 hours ago

$SPY $PFE and $MRK have the best longer-term swing setup for me right now. Possibly 30% trade right here

pnvoss Posted - 11 hours ago

$SPY I went long in $PFE and $MRK the past two days. Mfi and rsi readings reversing from very low readings and uptrending. Very undervalued and MRK is above 5 yr support. Good div stocks

Vandelay_Industries_Inc Posted - 11 hours ago

$MRK Attention Bots and Spammers. The company's managers (and other MRK shareholders) pay no mind to StockTwit posts with prayers and pitches for them to buyout your garbage penny stock. Knock it off. Nobody cares.

DonCorleone77 Posted - 12 hours ago

$PYXS $MRK Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck Pyxis Oncology (PYXS) announced preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple types of solid tumors. PYX-201, the company's lead clinical drug candidate, is a first-in-concept antibody-drug conjugate with a microtubule inhibitor payload that uniquely targets Extradomain-B Fibronectin, a non-cellular structural component within the tumor extracellular matrix. Significant clinical responses were observed in HNSCC. Among evaluable HNSCC patients treated at an identified dose range of PYX-201 from 3.6 - 5.4 mg/kg, a confirmed 50% objective response rate, or ORR, was observed, including one confirmed complete response, or CR, and two confirmed partial responses, or PR, by RECIST 1.1. The company additionally announces that it has entered into a clinical trial collaboration agreement with Merck (MRK) for a Pyxis Oncology-sponsored study of PYX-201 in combination with Merck's anti-PD-1 therapy, Keytruda in patients with 1L and 2L head and neck squamous cell carcinoma, HR+/HER2- breast cancer, and triple-negative breast cancer and sarcoma. The company expects to initiate the following HNSCC Phase 1 expansion studies: PYX-201 and Keytruda combination dose escalation and expansion study in 1L and 2L HNSCC with preliminary clinical data readout expected in the second half of 2025; PYX-201 monotherapy study in 2L and 3L HNSCC patients who are platinum and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the second half of 2025 and PYX-201 monotherapy study in 2L and 3L HNSCC patients who are EGFR and PD-1 inhibitor experienced, with preliminary clinical data readout expected in first half of 2026. Exploratory PYX-201 Phase 1 monotherapy expansion cohorts are planned in ovarian cancer, NSCLC, HR+/HER2- breast cancer, TNBC, and sarcoma, with preliminary clinical data expected in the second half of 2025. PYX-201 and Keytruda combination study in HR+/HER2- breast cancer, TNBC, and sarcoma with preliminary clinical data expected in the second half of 2025 and the first half of 2026. Preclinical studies of PYX-201 in combination with other agents in ovarian cancer and NSCLC to commence in 2025 to be followed by clinical studies with preliminary clinical data expected in 2026. PYX-201 demonstrated favorable preliminary tolerability profile data with low incidence of dose discontinuation, interruptions or delays due to treatment-related adverse events. Low incidence of Grade 3 or Grade 4 payload-related TRAEs within the identified dose range reinforce PYX-201's differentiated construct enabling enhanced molecular stability and differential expression of Extradomain-B in tumor tissue with negligible expression in normal tissues. The low incidence of Grade 1 or Grade 2 adverse events points to an attractive safety, given that it has been well tolerated and suitable for both monotherapy and combination therapy development. With respect to PK data, PYX-201 demonstrated increased stability in circulation, which we believe is due to its proprietary design of site-specific conjugation chemistry as compared to certain approved val-cit-monomethyl auristatin E ADCs with non-site-specific conjugation chemistry.

DevinTaylor__ Posted - 14 hours ago

$LLY $MRK $AZN nice move from TMO, are you going same ?

Noswimming Posted - 14 hours ago

@OneArrow @Hannibal_Smith @Fvalstounge @Cringe1 Without ending the continued manipulation, the only way they get to a $35M market cap is a partnership with big pharma or dilution to around 70M, assuming a nearly 100% increase in shares is going to cause a ripple effect in the current PS value. Short of FDA approval, I don't see any other news that overpowers the manipulation. While my BO valuation is a bit over the top, consider some of the recent acquisitions of small bios in phase 1 and early phase 2 trials that went for $3.3B up to $5B. Companies like $MRK and $BMY are looking to secure pipeline products, since no one knows how things will function with the new administration. It appears both RFK Jr. and Ramaswamy have a distaste for big pharma, so they may be out of the game for FDA control over the next 4 years. This gives companies like $BCTX in early ph 3 trials and positive ph2 data with big companies like $MRK & $INCY a powerful poker chip in negotiations.

wyoming2020 Posted - 15 hours ago

$PDSB $MRK could now buy back a bigger, much more further along pipeline for less than what they sold for 3 years ago. Thats smart business. If no partner soon, could be a blinking amber light that there is a more advanced peer lurking in the dark

mickeyp_ Posted - 15 hours ago

$MRNA market cap is 14 billion with like 8 billion in cash ... $LLY $MRK $PFE someone BUY THEM OUT

cea Posted - 16 hours ago

$SLS @PokerMunkee Your right, but then $SLS is a R&D small pharma without a real revenue stream; so the current price per share (PPS) is make believe and does not represent the actual value of either $SLS or the therapies. The actualized value for buy out / acquisition is the net present value (NPV) of discounted cash flows based on the total addressable market (TAM) times expected profit per treatment over probably 10 years. @GPS_OS_21_vs_SOC_5 and others have provided numbers for TAM and anticipated value per treatment. The only thing we really don’t have a grasp of is the marginal acceptable return (MAR) required by potential suitors. For example - this is speculative - $MRK may pursue a buy out of $SLS to combine Zeltherva with Keytruda and may accept a smaller return in order to protect Keytruda from potential generics. Also, Zeltherva has potential efficacy for not just blood but also solid cancers. I’ve not even spoken to the potential for SLS009.

Braveheart_13 Posted - 16 hours ago

$ALT So if these disclosures have been released in the past... it sounds like they have 3 month compensation timelines for certain parties who are serious/intent, so maybe $LLY and $MRK have been looking since August and they exceeded their DD timeline and are renewing the contract to continue DD? Nevermore

Braveheart_13 Posted - 16 hours ago

$ALT So $LLY and $MRK are the only contracts with lines that say Wells Fargo seeks investment banking compensation within 3 months... due diligence must have officially begun and this all lines up with my JPM timeline for a potential buyout

Braveheart_13 Posted - 16 hours ago

$ALT Now $AZN too... $PFE $LLY Wonder if $MRK is next? Maybe this means nothing but with all the latest developments with our obesity program, we'd be remiss if we didn't consider a bidding process may be in the works

Braveheart_13 Posted - 16 hours ago

$ALT Holy fuck. GREAT find team. Has the bidding war begun with $PFE and $LLY as the lead candidates? Wonder when $MRK will step in... we're a shoe in fit

arnolddiver Posted - 17 hours ago

$IBRX yup. Have u seen $MRK 6 month stock chart? The keytruda patent cliff is real. That slide was specifically for the big boys. PSS is basically saying Tik Tok time is running out Anktiva can help.

Braveheart_13 Posted - 17 hours ago

$ALT Pemvi vs the obesity landscape. Best in class baby, bar none! $MRK wants this for Christmas $LLY $NVO $VKTX

Braveheart_13 Posted - 18 hours ago

$ALT Paging $MRK let's go baby, we're the dream team. Acquire pemvi and take it supersonic.

RoidRagingBull Posted - 18 hours ago

$ALT $MRK 1 for 1 share exchange!

DefenseMania Posted - 18 hours ago

$GILD get in RCUS before GILD acquires them $14.45 A STEAL !!!!!!’ $AZN $BMY $LLY $MRK

ShadowyForeignExchange Posted - 18 hours ago

$MRK Upgrade? UPGRADE!

TheVulcanDevilWhale Posted - 18 hours ago

$MRK 🖖🏽😈🐳

Jimmyboy29 Posted - 19 hours ago

$MRK boom. Can see $100 today

Biotech2424 Posted - 19 hours ago

$CHRS Checkpoint $CKPT has twice the market cap of Coherus and their checkpoint inhibitor isn’t even approved yet. We have fda approved one and $350 million in revenues forecasted for 2025. $MRK

QuantumPulseTrader Posted - 19 hours ago

$MRK $SPGI LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

7Billiards Posted - 19 hours ago

$ALT $GILD $MRK $NVO $PFE class leading MASH data 50Bn TAM

GreenEnergy2022 Posted - 20 hours ago

$ALT Class leading MASH data, 500 mcap, MASH ph2 soon going into phs3. Madrigal & Viking with inferior data. "Pemvidutide reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after 12 weeks of treatment." $NVO $GILD $MRK $PFE

SchroederO Posted - 20 hours ago

$ABBV $MRK LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

PaytonWoodward__ Posted - 20 hours ago

[ $ABBV $MRK] LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?